Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719406 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A4ALDH1A1OPRK1LMNA | |
| SCHEMBL6715862 | 0.80 | CYP3A4 (0.49) | SLC6A2SLC6A4ALDH1A1LMNATRPM8 | |
| SCHEMBL3506072 | 0.76 | TACR3 (0.51) | ALDH1A1TACR3OPRK1LMNAKMT2A | |
| SCHEMBL11402402 | 0.73 | TRPM8 (0.49) | ALDH1A1LMNATRPM8SMN1; SMN2MEN1 | |
| SCHEMBL6714552 | 0.72 | TRPM8 (0.38) | SLC6A2SLC6A4ALDH1A1LMNATRPM8 | |
| SCHEMBL16830012 | 0.71 | OPRK1 (0.44) | TACR3OPRK1LMNASMN1; SMN2MEN1 | |
| SCHEMBL6825332 | 0.70 | SIGMAR1 (0.49) | SLC6A2SLC6A4ALDH1A1TACR3 | |
| SCHEMBL13050111 | 0.70 | TACR3 (0.48) | TACR3LMNAMEN1KMT2A | |
| SCHEMBL3150694 | 0.70 | LMNA (0.50) | ALDH1A1LMNATRPM8SMN1; SMN2MEN1 | |
| SCHEMBL6726593 | 0.70 | HDAC1 (0.44) | SLC6A2SLC6A4ALDH1A1S1PR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022528-A2 | ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | SLC6A2 22/4885SLC6A4 15/4885ALDH1A1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.